Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 8/20 | 0.57 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.45 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.44 |
| ▸ | CFD | P00746 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14434252 | 0.91 | F10 (0.56) | F10USP30KLKB1CFDNPSR1 | |
| SCHEMBL8471226 | 0.89 | F10 (0.54) | F10KLKB1CFDKMT2A | |
| SCHEMBL13104152 | 0.86 | F10 (0.52) | F10KLKB1CFDKMT2A | |
| SCHEMBL12101291 | 0.86 | F10 (0.52) | F10KLKB1CFDKMT2A | |
| SCHEMBL12101293 | 0.85 | F10 (0.53) | F10KLKB1CFDKMT2A | |
| SCHEMBL12371451 | 0.85 | F10 (0.48) | F10KLKB1CFDNPSR1KMT2A | |
| SCHEMBL15436018 | 0.85 | F10 (0.48) | F10KLKB1CFDNPSR1KMT2A | |
| SCHEMBL8230614 | 0.85 | F10 (0.48) | F10KLKB1CFD | |
| SCHEMBL12101317 | 0.85 | F10 (0.48) | F10KLKB1CFD | |
| SCHEMBL15436220 | 0.83 | F10 (0.46) | F10KLKB1CFDNPSR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003639-B2 | Substituted prolinamides, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| US-8003639-B2 | Substituted prolinamides, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| US-20090048231-A1 | SUBSTITUTED PROLINAMIDES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048231-A1 | SUBSTITUTED PROLINAMIDES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048231-A1 | SUBSTITUTED PROLINAMIDES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PREP, P4HA1, PPID | F10 1628/4885USP30 4112/4885KLKB1 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.